UNASSIGNED: The aim of the study was to evaluate the diagnostic accuracy of urinary neutrophil gelatinase- associated lipocalin (uNGAL) in @entity1 with @entity740 ( @entity740 ) as an early biomarker for contrast induced @entity810 (CI-AKI) and to investigate whether @entity1 with an uNGAL increase might benefit from an additional intravenous volume expansion with regard to CI-AKI-incidence. We performed a prospective randomized controlled trial in 617 @entity740 - @entity1 undergoing intra-arterial angiography. Urinary @entity15901 was measured the day before and 4-6hrs after angiography. In the event of a significant rise of uNGAL @entity1 were randomized either into Group A, who received intravenous saline post procedure or Group B, who did not receive post-procedural i.v. fluids. Ten @entity1 (1.62%) exhibited a significant rise of uNGAL after angiography and were randomized of whom one developed a CI-AKI. In the entire cohort the incidence of CI-AKI was 9.4% (58 @entity1 ) resulting in a specificity of 98.4% (95% CI: 97.0-99.3%) and a sensitivity of 1.72% (95% CI: 0.044-9.2%) of uNGAL for the diagnosis of CI-AKI. In this study uNGAL failed to predict CI-AKI and was an inadequate triage tool to guide an early intervention strategy to prevent CI-AKI. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01292317.

@entity15901 ( XXXX ) fails as an early predictor of contrast induced nephropathy in @entity740 (ANTI-CI-AKI study).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity15901 :: ('3934', 'Gene') :: ['NGAL'] @entity810 :: ('MESH:D058186', 'Disease') :: ['acute kidney injury'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']
@entity15901 :: (3934,Gene) :: ['NGAL']
